Marshall Wace, LLP Gain Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 196,026 shares of GANX stock, worth $331,283. This represents 0.0% of its overall portfolio holdings.
Number of Shares
196,026
Previous 91,738
113.68%
Holding current value
$331,283
Previous $187,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
37Shares Held
3.52MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$994,4120.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$956,7590.05% of portfolio
-
Jones Financial Companies Lllp428KShares$722,8130.0% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$476,9360.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$430,9330.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $20.1M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...